Codrituzumab

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameCodrituzumab
Drug Alias NamecodrituzumabumGC-33RO-5137382RG-7686PPMX-T001 +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsWnt signalling pathway inhibitorsGlypican-3 inhibitors +[4] 
TargetsGlypican-3
Therapy Area/IndicationsSolid tumoursCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSingapore +[13] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPerseus Proteomics Inc
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharma USA, Inc
Inactive CompaniesChugai Pharmaceutical Co LtdF. Hoffmann-La Roche Ltd
Active IndicationsSolid tumours
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A